Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results
1. ARTL reports positive interim Phase 2 results for ART27.13. 2. Drug targets cancer anorexia-cachexia syndrome, with no current FDA-approved treatment. 3. Interest from pharmaceutical companies may secure a partner for ART27.13. 4. CACS presents a multi-billion dollar market opportunity for ARTL. 5. CEO emphasizes potential for FDA approval, focusing on development partnerships.